Article
Cardiovascular adverse events associated with epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer: systematic review and network meta-analysis.
BMJ (Clinical research ed.) - 2 Sept 2025
Ma Zidong, Cao Fei, Liao Mingjuan, Min Rui, Zheng Rui, Sun Xiaolin, Chen Xinlin, Gong Yabin, Ai Sizhi, Kang Xiaohong
Abstract excerpt
OBJECTIVE: To evaluate the risk of cardiovascular adverse events associated with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer (NSCLC). DESIGN: Systematic review and network meta-analysis. DATA SOURCES: PubMed, Embase, Web of Science, Scopus, Cochrane Central Register of Controlled Trials, and three clinical trial registries, from...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.